Takeda Pharmaceutical Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Takeda Pharmaceutical stock has a target of 21, which predicts an increase of 31.99% from the current stock price of 15.91.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$21	$21	$21	$21
Change	+31.99%	+31.99%	+31.99%	+31.99%

Analyst Ratings

The average analyst rating for Takeda Pharmaceutical stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	3	3	3	3	3	3
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	3	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Michael Nedelcovych TD Cowen	TD Cowen	Buy Maintains $21	Buy	Maintains	$21	+31.99%	Jun 4, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

4,630.28B

from 4,505.72B

2.76%

from 4,505.72B

Revenue Next Year

4,700.59B

from 4,630.28B

1.52%

from 4,630.28B

EPS This Year

n/a

from -

EPS Next Year

n/a

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028
Period Ending	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027	Mar 31, 2028
Revenue	3,569.01B	4,027.48B	4,263.76B	4,581.55B	4,505.72B	4,630.28B	4,700.59B
Revenue Growth	11.61%	12.85%	5.87%	7.45%	-1.65%	2.76%	1.52%
EPS	145.87	201.94	91.16	67.23	-96.75	122.84	191.03
EPS Growth	-38.96%	38.44%	-54.86%	-26.25%	-	-	55.52%
Forward PE	-	-	-	-	-	20.95	13.47
No. Analysts	-	-	-	-	-	15	15

Financial currency is JPY. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2027	2028
High	4.7T	5.0T
Avg	4.6T	4.7T
Low	4.5T	4.4T

Revenue Growth

Revenue Growth	2027	2028
High	5.3%	8.2%
Avg	2.8%	1.5%
Low	-0.4%	-5.6%

EPS Forecast

EPS	2027	2028
High	-	-
Avg	-	-
Low	-	-

EPS Growth

EPS Growth	2028	2029
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.